The stock of Revance Therapeutics Inc (NASDAQ:RVNC) is a huge mover today! About 135,723 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 32.38% since April 4, 2016 and is downtrending. It has underperformed by 33.47% the S&P500.
The move comes after 6 months positive chart setup for the $370.76M company. It was reported on Nov, 4 by Barchart.com. We have $39.56 PT which if reached, will make NASDAQ:RVNC worth $715.57M more.

Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage

Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The rating was initiated by SunTrust on Wednesday, March 23 with “Buy”. The rating was downgraded by Zacks to “Hold” on Saturday, August 22. The rating was maintained by Suntrust Robinson with “Buy” on Tuesday, June 14. The firm has “Hold” rating by Brean Capital given on Tuesday, June 14. The rating was initiated by Guggenheim on Monday, November 23 with “Buy”.

According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTSÂ® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”

Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.32, from 1.07 in 2016Q1. The ratio is positive, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Nq Hcif Limited last reported 3.10M shares in the company. Utd National Bank Va holds 77,177 shares or 1.04% of its portfolio. Moreover, Nationwide Fund has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 33,556 shares. Rothschild Asset Mgmt owns 10,539 shares or 0% of their US portfolio. Iguana Healthcare Mgmt Ltd holds 0.55% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 100,000 shares. Nottingham Advsr reported 16,312 shares or 0.04% of all its holdings. has 11,769 shares for 0% of their US portfolio. State Of New Jersey Common Pension Fund D, a New Jersey-based fund reported 26,000 shares. Janney Montgomery Scott Ltd Liability Com holds 0% or 8,425 shares in its portfolio. Royal Bancorp Of Canada accumulated 0% or 19,228 shares. Blackrock holds 0% or 1,893 shares in its portfolio. Moreover, Utd Serv Automobile Association has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 33,761 shares. Tower Research Ltd Llc (Trc) holds 191 shares or 0% of its portfolio. Alliancebernstein Lp has 35,300 shares for 0% of their US portfolio. Lombard Odier Asset Management (Usa) holds 0.04% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 22,515 shares.

Insider Transactions: Since May 9, 2016, the stock had 0 buys, and 3 selling transactions for $212,629 net activity. Ruegg Curtis sold $16,180 worth of stock or 1,000 shares. 12,000 Revance Therapeutics Inc (NASDAQ:RVNC) shares with value of $178,199 were sold by Browne L Daniel.

Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.

RVNC Company Profile

Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.